BACKGROUND: In the population-based HIV impact assessment surveys, early infant diagnosis (EID) was provided to infants <18 months without a prior diagnosis. For the Namibia population-based HIV impact assessment (NAMPHIA), the GeneXpert platform was assessed for the feasibility of near POC EID testing compared with the standard Roche COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) platform. Quality assurance measures and turnaround time were compared to improve EID results reporting. METHODS: NAMPHIA participants were screened for HIV exposure using Determine HIV-1/2 rapid test; samples reactive on Determine received EID testing on the GeneXpert instrument and Xpert HIV-1 Qual assay using whole blood. Results were confirmed at the Namibia Institute of Pathology using dried blood spots on the Roche CAP/CTM platform per national guidelines. RESULTS: Of the 762 screened infants, 61 (8.0%) were Determine-reactive and considered HIV-exposed. Of the 61 exposed infants, 2 were found to be HIV-infected whereas 59 were negative on both GeneXpert and Roche platforms, achieving 100% concordance. Average turnaround time was 3.4 days for the Xpert HIV-1 Qual assay, and average time from collection to testing was 1.0 days for GeneXpert compared with 10.7 days for Roche. No samples failed using GeneXpert whereas 1 sample failed using Roche and was repeated. CONCLUSION: Quality POC EID testing is feasible in a national survey through extensive training and external quality assurance measures. The use of decentralized POC EID for national testing would provide rapid diagnosis and improve TATs which may prevent loss to follow-up, ensure linkage to care, and improve clinical outcomes for infants.
BACKGROUND: In the population-based HIV impact assessment surveys, early infant diagnosis (EID) was provided to infants <18 months without a prior diagnosis. For the Namibia population-based HIV impact assessment (NAMPHIA), the GeneXpert platform was assessed for the feasibility of near POC EID testing compared with the standard Roche COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) platform. Quality assurance measures and turnaround time were compared to improve EID results reporting. METHODS: NAMPHIA participants were screened for HIV exposure using Determine HIV-1/2 rapid test; samples reactive on Determine received EID testing on the GeneXpert instrument and Xpert HIV-1 Qual assay using whole blood. Results were confirmed at the Namibia Institute of Pathology using dried blood spots on the Roche CAP/CTM platform per national guidelines. RESULTS: Of the 762 screened infants, 61 (8.0%) were Determine-reactive and considered HIV-exposed. Of the 61 exposed infants, 2 were found to be HIV-infected whereas 59 were negative on both GeneXpert and Roche platforms, achieving 100% concordance. Average turnaround time was 3.4 days for the Xpert HIV-1 Qual assay, and average time from collection to testing was 1.0 days for GeneXpert compared with 10.7 days for Roche. No samples failed using GeneXpert whereas 1 sample failed using Roche and was repeated. CONCLUSION: Quality POC EID testing is feasible in a national survey through extensive training and external quality assurance measures. The use of decentralized POC EID for national testing would provide rapid diagnosis and improve TATs which may prevent loss to follow-up, ensure linkage to care, and improve clinical outcomes for infants.
Authors: Artur Ramos; Shon Nguyen; Albert Garcia; Shambavi Subbarao; John N Nkengasong; Dennis Ellenberger Journal: J Virol Methods Date: 2012-12-07 Impact factor: 2.014
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Hetal K Patel; Yen T Duong; Sehin Birhanu; Trudy Dobbs; Kathryn Lupoli; Carole Moore; Mervi Detorio; Katrina Sleeman; Julius Manjengwa; Floris Wray-Gordon; Daniel Yavo; Keisha Jackson; Robert A Domaoal; Ernest L Yufenyuy; Shanmugam Vedapuri; Clement B Ndongmo; Francis M Ogollah; Tafadzwa Dzinamarira; Paul Rubinstein; Karampreet K Sachathep; Melissa Metz; Herbert Longwe; Suzue Saito; Kristin Brown; Andrew C Voetsch; Bharat S Parekh Journal: J Acquir Immune Defic Syndr Date: 2021-08-01 Impact factor: 3.731
Authors: Suzue Saito; Yen T Duong; Melissa Metz; Kiwon Lee; Hetal Patel; Katrina Sleeman; Julius Manjengwa; Francis M Ogollah; Webster Kasongo; Rick Mitchell; Owen Mugurungi; Frank Chimbwandira; Crispin Moyo; Vusumuzi Maliwa; Helecks Mtengo; Tepa Nkumbula; Clement B Ndongmo; Nora Skutayi Vere; Geoffrey Chipungu; Bharat S Parekh; Jessica Justman; Andrew C Voetsch Journal: J Int AIDS Soc Date: 2017-11 Impact factor: 5.396